05/15/23 8:45 AMAMEX : AIM earningsAIM ImmunoTech Reports First Quarter Financial Results and Provides Pipeline Update– Continued execution across pipeline positions AIM to achieve multiple clinical and regulatory value-driving milestones throughout 2023 – Lead clinical program, Phase 2 locally advance pancreatic cancer study, expected to enroll first patient this quarter – Phase 2 advanced recurrent ovarianRHEA-AIneutral
05/09/23 8:50 AMAMEX : AIM earningsAIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and WebcastAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, theRHEA-AIneutral
04/12/23 8:35 AMAMEX : AIM managementAIM ImmunoTech Appoints Preeminent Biotechnology Pioneer, W. Neal Burnette, Ph.D., as Chairman of its Scientific Advisory Board (SAB)AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on theRHEA-AIneutral
04/04/23 8:45 AMAMEX : AIM clinical trialcovid-19AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID ConditionsAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research andRHEA-AIpositive
04/03/23 6:30 AMAMEX : AIM earningsAIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones – Company to host inaugural conference call and webcast today at 8:30 AM ET OCALA, Fla., April 03, 2023RHEA-AIpositive
03/30/23 8:45 AMAMEX : AIM managementAIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance ExpertiseAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases — including COVID-19, theRHEA-AIvery positive
03/27/23 9:05 AMAMEX : AIM conferencesearningsAIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and WebcastAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, theRHEA-AIneutral
03/16/23 8:45 AMAMEX : AIM AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus DiseaseAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused onRHEA-AIneutral
03/08/23 8:45 AMAMEX : AIM AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus DiseaseAIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including COVID-19, theRHEA-AIneutral
03/06/23 8:45 AMAMEX : AIM AIM ImmunoTech Issues Letter to StockholdersYear marked by noteworthy operational execution and clinical development progress across pipeline Company reiterates commitment to continued communication and activity with the investment and scientific communities Poised to achieve multiple clinical and regulatory value-driving milestones in 2023RHEA-AIvery positive